Publication at Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové |
2021
Abstract
Oral cladribine is a high efficacy disease-modifying drug for treatment of multiple sclerosis. Its mode of action represents a selective immune-reconstitution resulting in simply dosing in two annual curses followed by a sustained period of a potential remission.
Our work is aimed to an initiation of oral cladribine treatment, monitoring schedule and types of terapeutic response. Consequent treatment options are suggested based on eventual disease activity after cladribine courses.
Furthermore, cladribine is discussed from perspective of pregnancy planning and vaccination.